A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma
Conclusion At 15 mg/kg weekly, GSK3052230 was well tolerated in combination with pemetrexed/cisplatin and durable responses were observed. Importantly, AEs associated with small molecule inhibitors of FGFR were not observed, as predicted by the unique mechanism of action of this drug.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Alimta | Asbestosis | Cancer | Cancer & Oncology | Drugs & Pharmacology | Investigational New Drugs | Mesothelioma | Skin | Study | Toxicology | Vitamin A